Some of the elevated risk of prostate cancer among those with a family history of the disease may be due to increased prostate cancer testing and detection in this population. These findings were recently published in the Journal of the National Cancer Institute.
Among men with early-stage prostate cancer, assessment of other health problems may help guide prostate cancer treatment decisions; men who are likely to die of causes other than prostate cancer may not benefit from aggressive prostate cancer treatment. These findings were published in the Archives of Internal Medicine.
Recent research indicates that 64% of urologists and 80% of primary care physicians surveyed do not prescribe finasteride for prevention of prostate cancer in high-risk men. These findings were recently published in the journal Cancer Epidemiology, Biomarkers & Prevention.
Among men with metastatic, hormone-refractory prostate cancer, the immunotherapy agent Provenge® (sipuleucel-T) improves survival by roughly four months. The findings from this Phase III study were recently published in The New England Journal of Medicine.
A systematic review of 47 studies evaluating treatment for melanoma, head and neck cancer, genitourinary cancers, gynecologic cancers, and sarcoma indicates that lymphedema is a common side effect of treatment for these diseases.
In a large U.S. cancer database, 14% of prostate cancer diagnoses occurred among men with a prostate-specific antigen (PSA) level of 4.0 ng/mL or lower. More than half of these men had cancer that was considered “low-risk,” but roughly three-quarters were treated aggressively with radical prostatectomy or radiation therapy. These results were published in the Archives of Internal Medicine.
Statin use may reduce the risk of prostate cancer recurrence among men who have undergone a radical prostatectomy. These findings were recently published in the journal Cancer.
Active surveillance—sometimes referred to as “watchful waiting”—may be acceptable treatment for low-risk prostate cancer, according to the results of a study published early online in the Journal of the National Cancer Institute.
Jevtana® (cabazitaxel), a new chemotherapy drug, was approved for use in combination with prednisone for thetreatment of patients with metastatic hormone-refractory prostate cancer previously treated with a Taxotere® (docetaxel)-containing regimen.
The addition of radiation therapy to hormone therapy reduces the risk of prostate cancer death by 43% among men with locally advanced or high-risk prostate cancer compared with hormone therapy alone, according to the results of a phase III study presented at the 2010 annual meeting of the American Society of Clinical Oncology.
